{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.5","upperLimit":"31.7","value":"26.1"},{"comment":"Median DOR for group 2 has not been attained.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. The median DOR with 95%CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG000","title":"LCD (Cyclophosphamide 300 mg/m^2)"},{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG001","title":"LCD (Cyclophosphamide 300 mg)"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a partial response(PR) or better were evaluable for this analysis.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}